Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Liarozole · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Liarozole | DRUG | - |
Inclusion Criteria: * Subjects of either sex aged 14 years or older. * Clinical diagnosis of lamellar ichthyosis * Women of childbearing potential should use appropriate contraception * Women of childbearing potential should have a negative pregnancy test at screening visit. * Subjects are, except ...
Liarozole is being studied for the treatment of lamellar ichthyosis, a rare inherited skin disorder. It is an investigational small molecule developed by GSK plc and has reached Phase 2 clinical development. It has not been approved for any indication.
Liarozole is being developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 2 clinical program evaluating the drug in lamellar ichthyosis.
Liarozole is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The drug remains investigational and has not been approved by the FDA or any other regulatory agency for lamellar ichthyosis.
Liarozole has been evaluated in one completed Phase 2 trial, NCT00282724, titled "Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis." The randomized, double-blind study enrolled 98 participants across Belgium, Canada, the Dominican Republic, France, Germany, Italy, the Netherlands, Norway, and Sweden.
The completed Phase 2 trial of liarozole, NCT00282724, enrolled 98 participants aged 14 years and older of any sex. It was a randomized, double-blind study comparing two doses of liarozole against placebo in patients with lamellar ichthyosis. Healthy volunteers were not included.